» Articles » PMID: 28170181

The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar

Overview
Date 2017 Feb 8
PMID 28170181
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The growing direct-to-consumer, stem cell clinic industry in the U.S. uses a number of strategies for patient recruitment, including self-styled educational seminars, which may reach thousands of members of the public annually. Here I report on a first-hand experience at such a seminar that I recently attended. Numerous specific medical claims were made at the seminar: no potential for rejection; no side effects, including no pain; proven efficacy for a variety of conditions, including in particular arthritis and pain; and U.S. Food and Drug Administration approval. I discuss the potential impact of these kinds of seminars on the public and on the stem cell field. Stem Cells Translational Medicine 2017;6:14-16.

Citing Articles

Assessment of Short-Term Effects of Cell Transplantation in Cirrhosis DUE to HCV.

Astrakhanov A, Saparbayev S, Amanzholkyzy A, Iskakova A, Nurlanova G, Kurmangazin M Asian Pac J Cancer Prev. 2024; 25(6):2099-2104.

PMID: 38918672 PMC: 11382860. DOI: 10.31557/APJCP.2024.25.6.2099.


The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation.

Arthurs J, Martin Lillie C, Master Z, Shapiro S J Prim Care Community Health. 2022; 13:21501319221121460.

PMID: 36112830 PMC: 9476238. DOI: 10.1177/21501319221121460.


Online seminars as an information source for direct-to-consumer stem cell therapy.

Hassoun M, Golub S, Greenfield S, Grill J, Cummings B Regen Med. 2021; 17(2):81-90.

PMID: 34949108 PMC: 10694786. DOI: 10.2217/rme-2021-0070.


Weighing up the evidence used by direct-to-consumer stem cell businesses.

Cook M, Richey A, Brafman D, Frow E Stem Cell Reports. 2021; 16(12):2852-2860.

PMID: 34767748 PMC: 8693621. DOI: 10.1016/j.stemcr.2021.10.007.


Outer Retinal Cell Replacement: Putting the Pieces Together.

Ludwig A, Gamm D Transl Vis Sci Technol. 2021; 10(10):15.

PMID: 34724034 PMC: 8572485. DOI: 10.1167/tvst.10.10.15.


References
1.
Regenberg A, Hutchinson L, Schanker B, Mathews D . Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells. 2009; 27(9):2312-9. DOI: 10.1002/stem.132. View

2.
Knoepfler P . From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev. 2014; 82-83:192-6. PMC: 4398607. DOI: 10.1016/j.addr.2014.12.001. View

3.
Turner L, Knoepfler P . Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell. 2016; 19(2):154-157. DOI: 10.1016/j.stem.2016.06.007. View

4.
Turner L . US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions. Regen Med. 2015; 10(4):397-402. DOI: 10.2217/rme.15.10. View

5.
Knoepfler P . When patients reach out, scientists should reach back carefully. Nat Med. 2016; 22(3):230. DOI: 10.1038/nm0316-230. View